SALA LUCA

Hiniesto-Iñigo, I., Sridhar, A., Louradour, J., Cruz, A., Lundholm, S., Jauregi-Miguel, A., et al. (2025). Rescue of loss-of-function long QT syndrome-associated mutations in KV7.1/KCNE1 by the endocannabinoid N-arachidonoyl-L-serine (ARA-S). BRITISH JOURNAL OF PHARMACOLOGY [10.1111/bph.70008]. Detail

Sesti, V., Magni, A., Moschetta, M., Florindi, C., Pfeffer, M., Difrancesco, M., et al. (2025). Membrane-targeted push-pull azobenzenes for the optical modulation of membrane potential. LIGHT, SCIENCE & APPLICATIONS, 14(1) [10.1038/s41377-024-01669-x]. Detail

Maione, A., Iengo, L., Sala, L., Massaiu, I., Chiesa, M., Lippi, M., et al. (2024). Cardiomyocyte and stromal cell cross-talk influences the pathogenesis of arrhythmogenic cardiomyopathy: a multi-level analysis uncovers DLK1-NOTCH pathway role in fibro-adipose remodelling. CELL DEATH DISCOVERY, 10(1) [10.1038/s41420-024-02232-8]. Detail

Crotti, L., Neves, R., Dagradi, F., Musu, G., Giannetti, F., Bos, J., et al. (2024). Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients. CIRCULATION, 150(7), 531-543 [10.1161/CIRCULATIONAHA.124.068959]. Detail

Sala, L., Khudiakov, A., Mura, M., Leonov, V., Giannetti, F., Crotti, L., et al. (2024). Use of hiPSC-derived cardiomyocytes to study LQTS-variant specific proarrhythmic effects of drugs. VASCULAR PHARMACOLOGY, 155(June 2024) [10.1016/j.vph.2024.107347]. Detail